{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:02:31Z","timestamp":1789635751738,"version":"4.0.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203364"],"award-info":[{"award-number":["82203364"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biochem Biophys"],"DOI":"10.1007\/s12013-026-02118-9","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:17:24Z","timestamp":1783941444000},"page":"4273-4286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["RHBDD2 Confers Insensitivity of Esophageal Squamous Cell Carcinoma to Cisplatin by Inhibiting Ferroptosis Through the Wnt3a\/\u03b2-Catenin\/FTH1 Axis"],"prefix":"10.1007","volume":"84","author":[{"given":"Youxiang","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"issue":"3","key":"2118_CR1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","volume":"163","author":"E Morgan","year":"2022","unstructured":"Morgan, E., Soerjomataram, I., Rumgay, H., Coleman, H. G., Thrift, A. P., Vignat, J., Laversanne, M., Ferlay, J., & Arnold, M. (2022). The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020. Gastroenterology, 163(3), 649\u2013658. e642.","journal-title":"Gastroenterology"},{"issue":"2","key":"2118_CR2","first-page":"1","volume":"30","author":"Y Baba","year":"2017","unstructured":"Baba, Y., Saeki, H., Nakashima, Y., Oki, E., Shigaki, H., Yoshida, N., Watanabe, M., Maehara, Y., & Baba, H. (2017). Review of chemotherapeutic approaches for operable and inoperable esophageal squamous cell carcinoma. Diseases of the esophagus: official journal of the International Society for Diseases of the Esophagus, 30(2), 1\u20137.","journal-title":"Diseases of the esophagus: official journal of the International Society for Diseases of the Esophagus"},{"key":"2118_CR3","doi-asserted-by":"publisher","first-page":"1397960","DOI":"10.3389\/fonc.2024.1397960","volume":"14","author":"H Shi","year":"2024","unstructured":"Shi, H., Tan, Y., Ma, C., Wei, Y., Shi, F., Wang, J., Xu, C., & Liang, R. (2024). Efficacy and safety evaluation of first-line systemic treatments for unresectable esophageal squamous cell carcinoma: a network meta-analysis. Frontiers In Oncology, 14, 1397960.","journal-title":"Frontiers In Oncology"},{"issue":"1","key":"2118_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12032-023-02237-w","volume":"41","author":"R Fu","year":"2023","unstructured":"Fu, R., Zhao, B., Chen, M., Fu, X., Zhang, Q., Cui, Y., Hu, X., & Zhou, W. (2023). Moving beyond cisplatin resistance: mechanisms, challenges, and prospects for overcoming recurrence in clinical cancer therapy. Medical Oncology, 41(1), 9.","journal-title":"Medical Oncology"},{"issue":"2","key":"2118_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s00018-022-04131-6","volume":"79","author":"M Lohan-Codeco","year":"2022","unstructured":"Lohan-Codeco, M., Barambo-Wagner, M. L., Nasciutti, L. E., Ribeiro Pinto, L. F., Meireles Da Costa, N., & Palumbo, A. Jr. (2022). Molecular mechanisms associated with chemoresistance in esophageal cancer. Cellular and molecular life sciences: CMLS, 79(2), 116.","journal-title":"Cellular and molecular life sciences: CMLS"},{"key":"2118_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3389\/fphar.2020.00343","volume":"11","author":"J Zhou","year":"2020","unstructured":"Zhou, J., Kang, Y., Chen, L., Wang, H., Liu, J., Zeng, S., & Yu, L. (2020). The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents. Frontiers In Pharmacology, 11, 343.","journal-title":"Frontiers In Pharmacology"},{"issue":"15","key":"2118_CR7","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012). Molecular mechanisms of cisplatin resistance. Oncogene, 31(15), 1869\u20131883.","journal-title":"Oncogene"},{"issue":"1","key":"2118_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-019-0720-y","volume":"12","author":"Y Mou","year":"2019","unstructured":"Mou, Y., Wang, J., Wu, J., He, D., Zhang, C., Duan, C., & Li, B. (2019). Ferroptosis, a new form of cell death: opportunities and challenges in cancer. Journal Of Hematology & Oncology, 12(1), 34.","journal-title":"Journal Of Hematology & Oncology"},{"issue":"4","key":"2118_CR9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang, X., Stockwell, B. R., & Conrad, M. (2021). Ferroptosis: mechanisms, biology and role in disease. Nature reviews Molecular cell biology, 22(4), 266\u2013282.","journal-title":"Nature reviews Molecular cell biology"},{"issue":"1","key":"2118_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41392-024-01969-z","volume":"9","author":"Q Ru","year":"2024","unstructured":"Ru, Q., Li, Y., Chen, L., Wu, Y., Min, J., & Wang, F. (2024). Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects. Signal Transduct Target Ther, 9(1), 271.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"2118_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.31083\/j.fbl2808182","volume":"28","author":"X Shi","year":"2023","unstructured":"Shi, X., Zhang, A., Lu, J., Wang, X., Yi, C., & Yang, F. (2023). An Overview of Heavy Chain Ferritin in Cancer. Front Biosci (Landmark Ed), 28(8), 182.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"7","key":"2118_CR12","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"22","author":"G Lei","year":"2022","unstructured":"Lei, G., Zhuang, L., & Gan, B. (2022). Targeting ferroptosis as a vulnerability in cancer. Nature Reviews Cancer, 22(7), 381\u2013396.","journal-title":"Nature Reviews Cancer"},{"issue":"1","key":"2118_CR13","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41392-023-01606-1","volume":"8","author":"S Sun","year":"2023","unstructured":"Sun, S., Shen, J., Jiang, J., Wang, F., & Min, J. (2023). Targeting ferroptosis opens new avenues for the development of novel therapeutics. Signal Transduct Target Ther, 8(1), 372.","journal-title":"Signal Transduct Target Ther"},{"key":"2118_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.canlet.2020.02.015","volume":"483","author":"Y Su","year":"2020","unstructured":"Su, Y., Zhao, B., Zhou, L., Zhang, Z., Shen, Y., Lv, H., AlQudsy, L. H. H., & Shang, P. (2020). Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs. Cancer Letters, 483, 127\u2013136.","journal-title":"Cancer Letters"},{"issue":"1","key":"2118_CR15","doi-asserted-by":"publisher","first-page":"2223377","DOI":"10.1080\/15384047.2023.2223377","volume":"24","author":"H Chen","year":"2023","unstructured":"Chen, H., Wang, L., Liu, J., Wan, Z., Zhou, L., Liao, H., & Wan, R. (2023). LncRNA ITGB2-AS1 promotes cisplatin resistance of non-small cell lung cancer by inhibiting ferroptosis via activating the FOSL2\/NAMPT axis. Cancer Biology & Therapy, 24(1), 2223377.","journal-title":"Cancer Biology & Therapy"},{"issue":"4","key":"2118_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41419-024-06671-0","volume":"15","author":"F Liu","year":"2024","unstructured":"Liu, F., Tang, L., Liu, H., Chen, Y., Xiao, T., Gu, W., Yang, H., Wang, H., & Chen, P. (2024). Cancer-associated fibroblasts secrete FGF5 to inhibit ferroptosis to decrease cisplatin sensitivity in nasopharyngeal carcinoma through binding to FGFR2. Cell Death And Disease, 15(4), 279.","journal-title":"Cell Death And Disease"},{"issue":"12","key":"2118_CR17","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1016\/j.bbamem.2013.03.025","volume":"1828","author":"N Bergbold","year":"2013","unstructured":"Bergbold, N., & Lemberg, M. K. (2013). Emerging role of rhomboid family proteins in mammalian biology and disease. Biochimica et biophysica acta, 1828(12), 2840\u20132848.","journal-title":"Biochimica et biophysica acta"},{"issue":"3","key":"2118_CR18","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12192-013-0466-3","volume":"19","author":"E Lacunza","year":"2014","unstructured":"Lacunza, E., Rabassa, M. E., Canzoneri, R., Pellon-Maison, M., Croce, M. V., Aldaz, C. M., & Abba, M. C. (2014). Identification of signaling pathways modulated by RHBDD2 in breast cancer cells: a link to the unfolded protein response. Cell stress & chaperones, 19(3), 379\u2013388.","journal-title":"Cell stress & chaperones"},{"issue":"1","key":"2118_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s11658-024-00532-6","volume":"29","author":"Y Li","year":"2024","unstructured":"Li, Y., Zhou, Z., Qu, J., Gong, P., Wei, Y., & Sun, Y. (2024). Role of microRNA-4739 in enhancing cisplatin chemosensitivity by negative regulation of RHBDD2 in human cervical cancer cells. Cellular & Molecular Biology Letters, 29(1), 20.","journal-title":"Cellular & Molecular Biology Letters"},{"issue":"6","key":"2118_CR20","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1007\/s13277-012-0503-3","volume":"33","author":"E Lacunza","year":"2012","unstructured":"Lacunza, E., Canzoneri, R., Rabassa, M. E., Zwenger, A., Segal-Eiras, A., Croce, M. V., & Abba, M. C. (2012). RHBDD2: a 5-fluorouracil responsive gene overexpressed in the advanced stages of colorectal cancer. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine, 33(6), 2393\u20132399.","journal-title":"Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine"},{"issue":"8","key":"2118_CR21","doi-asserted-by":"publisher","first-page":"165810","DOI":"10.1016\/j.bbadis.2020.165810","volume":"1866","author":"S Palma","year":"2020","unstructured":"Palma, S., Raffa, C. I., Garcia-Fabiani, M. B., Ferretti, V. A., Zwenger, A., Perez Verdera, P. V., Llontop, A., Rojas Bilbao, E., Cuartero, V., Abba, M. C., et al. (2020). RHBDD2 overexpression promotes a chemoresistant and invasive phenotype to rectal cancer tumors via modulating UPR and focal adhesion genes. Biochimica et biophysica acta Molecular basis of disease, 1866(8), 165810.","journal-title":"Biochimica et biophysica acta Molecular basis of disease"},{"key":"2118_CR22","doi-asserted-by":"publisher","unstructured":"Ding, Y., Zhou, L., He, X., Li, L., & Wang, X. (2025). Rhomboid Domain Containing 2 (RHBDD2) is Upregulated and Responds to Cisplatin-Induced DNA Damage in Esophageal Cancer. Biochem Genet. https:\/\/doi.org\/10.1007\/s10528-025-11118-y","DOI":"10.1007\/s10528-025-11118-y"},{"issue":"5","key":"2118_CR23","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1002\/jcp.29317","volume":"235","author":"Y Ding","year":"2020","unstructured":"Ding, Y., Hao, K., Li, Z., Ma, R., Zhou, Y., Zhou, Z., Wei, M., Liao, Y., Dai, Y., Yang, Y., et al. (2020). c-Fos separation from Lamin A\/C by GDF15 promotes colon cancer invasion and metastasis in inflammatory microenvironment. Journal Of Cellular Physiology, 235(5), 4407\u20134421.","journal-title":"Journal Of Cellular Physiology"},{"issue":"4","key":"2118_CR24","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.7150\/ijbs.80775","volume":"19","author":"Q Lin","year":"2023","unstructured":"Lin, Q., Li, S., Jin, H., Cai, H., Zhu, X., Yang, Y., Wu, J., Qi, C., Shao, X., Li, J., et al. (2023). Mitophagy alleviates cisplatin-induced renal tubular epithelial cell ferroptosis through ROS\/HO-1\/GPX4 axis. International Journal Of Biological Sciences, 19(4), 1192\u20131210.","journal-title":"International Journal Of Biological Sciences"},{"issue":"1","key":"2118_CR25","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/s12935-024-03570-4","volume":"24","author":"Y Yan","year":"2024","unstructured":"Yan, Y., Huang, Z., Zhu, Z., Wang, Y., Cao, X., Yang, C., Jiang, J., Xia, S., & Shen, B. (2024). IMP2 drives chemoresistance by repressing cisplatin-induced apoptosis and ferroptosis via activation of IPO4 and SLC7A11 under hypoxia in bladder cancer. Cancer Cell International, 24(1), 386.","journal-title":"Cancer Cell International"},{"key":"2118_CR26","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1146\/annurev-biochem-040320-103615","volume":"91","author":"EY Rim","year":"2022","unstructured":"Rim, E. Y., Clevers, H., & Nusse, R. (2022). The Wnt Pathway: From Signaling Mechanisms to Synthetic Modulators. Annual Review Of Biochemistry, 91, 571\u2013598.","journal-title":"Annual Review Of Biochemistry"},{"issue":"2","key":"2118_CR27","doi-asserted-by":"publisher","first-page":"230","DOI":"10.2174\/09298673113209990181","volume":"21","author":"M Shoeb","year":"2014","unstructured":"Shoeb, M., Ansari, N. H., Srivastava, S. K., & Ramana, K. V. (2014). 4-Hydroxynonenal in the pathogenesis and progression of human diseases. Current Medicinal Chemistry, 21(2), 230\u2013237.","journal-title":"Current Medicinal Chemistry"},{"issue":"8","key":"2118_CR28","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41571-023-00774-x","volume":"20","author":"X Deng","year":"2023","unstructured":"Deng, X., Qing, Y., Horne, D., Huang, H., & Chen, J. (2023). The roles and implications of RNA m6A modification in cancer. Nature Reviews. Clinical Oncology, 20(8), 507\u2013526.","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"2118_CR29","doi-asserted-by":"publisher","first-page":"103035","DOI":"10.1016\/j.redox.2024.103035","volume":"70","author":"M Shen","year":"2024","unstructured":"Shen, M., Cao, S., Long, X., Xiao, L., Yang, L., Zhang, P., Li, L., Chen, F., Lei, T., Gao, H., et al. (2024). DNAJC12 causes breast cancer chemotherapy resistance by repressing doxorubicin-induced ferroptosis and apoptosis via activation of AKT. Redox Biology, 70, 103035.","journal-title":"Redox Biology"},{"key":"2118_CR30","doi-asserted-by":"publisher","first-page":"100960","DOI":"10.1016\/j.drup.2023.100960","volume":"68","author":"R Qi","year":"2023","unstructured":"Qi, R., Bai, Y., Li, K., Liu, N., Xu, Y., Dal, E., Wang, Y., Lin, R., Wang, H., Liu, Z., et al. (2023). Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs. Drug Resistance Updates : Reviews And Commentaries In Antimicrobial And Anticancer Chemotherapy, 68, 100960.","journal-title":"Drug Resistance Updates : Reviews And Commentaries In Antimicrobial And Anticancer Chemotherapy"},{"key":"2118_CR31","doi-asserted-by":"publisher","first-page":"102952","DOI":"10.1016\/j.redox.2023.102952","volume":"68","author":"Z Xu","year":"2023","unstructured":"Xu, Z., Wang, X., Sun, W., Xu, F., Kou, H., Hu, W., Zhang, Y., Jiang, Q., Tang, J., & Xu, Y. (2023). RelB-activated GPX4 inhibits ferroptosis and confers tamoxifen resistance in breast cancer. Redox Biology, 68, 102952.","journal-title":"Redox Biology"},{"key":"2118_CR32","doi-asserted-by":"publisher","first-page":"100916","DOI":"10.1016\/j.drup.2022.100916","volume":"66","author":"Y Wang","year":"2023","unstructured":"Wang, Y., Wu, X., Ren, Z., Li, Y., Zou, W., Chen, J., & Wang, H. (2023). Overcoming cancer chemotherapy resistance by the induction of ferroptosis. Drug Resistance Updates : Reviews And Commentaries In Antimicrobial And Anticancer Chemotherapy, 66, 100916.","journal-title":"Drug Resistance Updates : Reviews And Commentaries In Antimicrobial And Anticancer Chemotherapy"},{"issue":"1","key":"2118_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","volume":"21","author":"C Zhang","year":"2022","unstructured":"Zhang, C., Liu, X., Jin, S., Chen, Y., & Guo, R. (2022). Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Molecular Cancer, 21(1), 47.","journal-title":"Molecular Cancer"},{"issue":"10","key":"2118_CR34","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.bbadis.2009.07.006","volume":"1792","author":"MC Abba","year":"2009","unstructured":"Abba, M. C., Lacunza, E., Nunez, M. I., Colussi, A., Isla-Larrain, M., Segal-Eiras, A., Croce, M. V., & Aldaz, C. M. (2009). Rhomboid domain containing 2 (RHBDD2): a novel cancer-related gene over-expressed in breast cancer. Biochimica et biophysica acta, 1792(10), 988\u2013997.","journal-title":"Biochimica et biophysica acta"},{"issue":"2","key":"2118_CR35","first-page":"909","volume":"40","author":"R Canzoneri","year":"2018","unstructured":"Canzoneri, R., Rabassa, M. E., Gurruchaga, A., Ferretti, V., Palma, S., Isla-Larrain, M., Croce, M. V., Lacunza, E., & Abba, M. C. (2018). Alternative splicing variant of RHBDD2 is associated with cell stress response and breast cancer progression. Oncology reports, 40(2), 909\u2013915.","journal-title":"Oncology reports"},{"key":"2118_CR36","doi-asserted-by":"publisher","unstructured":"Shen, J., & Ding, Y. (2025). Multifaceted roles of insulin\u2013like growth factor 2 mRNA binding protein 2 in human cancer (Review). Mol Med Rep 31(3). https:\/\/doi.org\/10.3892\/mmr.2025.13441","DOI":"10.3892\/mmr.2025.13441"},{"issue":"12","key":"2118_CR37","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/j.ccell.2022.10.004","volume":"40","author":"H Weng","year":"2022","unstructured":"Weng, H., Huang, F., Yu, Z., Chen, Z., Prince, E., Kang, Y., Zhou, K., Li, W., Hu, J., Fu, C., et al. (2022). The m(6)A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell, 40(12), 1566\u20131582. e1510.","journal-title":"Cancer Cell"},{"issue":"9","key":"2118_CR38","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1038\/s41375-022-01651-9","volume":"36","author":"P Feng","year":"2022","unstructured":"Feng, P., Chen, D., Wang, X., Li, Y., Li, Z., Li, B., Zhang, Y., Li, W., Zhang, J., Ye, J., et al. (2022). Inhibition of the m(6)A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemia. Leukemia, 36(9), 2180\u20132188.","journal-title":"Leukemia"},{"issue":"2","key":"2118_CR39","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1021\/acschembio.1c00833","volume":"17","author":"C Dahlem","year":"2022","unstructured":"Dahlem, C., Abuhaliema, A., Kessler, S. M., Kr\u00f6hler, T., Zoller, B. G. E., Chanda, S., Wu, Y., Both, S., M\u00fcller, F., Lepikhov, K., et al. (2022). First Small-Molecule Inhibitors Targeting the RNA-Binding Protein IGF2BP2\/IMP2 for Cancer Therapy. ACS chemical biology, 17(2), 361\u2013375.","journal-title":"ACS chemical biology"}],"container-title":["Cell Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-026-02118-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12013-026-02118-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-026-02118-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:15:47Z","timestamp":1789632947000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12013-026-02118-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["2118"],"URL":"https:\/\/doi.org\/10.1007\/s12013-026-02118-9","relation":{},"ISSN":["1559-0283"],"issn-type":[{"value":"1559-0283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"25 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}